[Programmed Necrosis Inducers for Cancer Treatment]

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Cell Biology

Background:

• Programmed necrosis is a Caspase-independent cell death pathway.
• Key mediators include receptor-interacting protein kinase-1 (RIPK1), receptor-interacting protein kinase-3 (RIPK3), and mixed lineage kinase domain-like protein (MLKL).
• Programmed necrosis plays a dual role in tumor development, offering therapeutic potential.

Purpose of the Study:

• To summarize the mechanisms of programmed necrosis and its relationship with tumors.
• To review the antitumor activity of various programmed necrosis inducers.
• To highlight novel therapeutic candidates for cancer treatment.

Main Methods:

• Literature review of programmed necrosis mechanisms and tumor interactions.
• Focused analysis of antitumor activities of programmed necrosis inducers.
• Categorization of inducers: natural products, chemotherapeutics, death receptor ligands, kinase inhibitors, inorganic salts, metal complexes, and metal nanoparticles.

Main Results:

• Programmed necrosis can be regulated to control tumor development.
• Inducing programmed necrosis demonstrates potential anti-tumor activity.
• This approach is effective in overcoming tumor resistance to apoptosis.

Conclusions:

• Programmed necrosis inducers represent promising therapeutic candidates for cancer treatment.
• Especially effective for tumors resistant to apoptosis.
• Further research into these agents could lead to novel cancer therapies.